Cancer

Chemotherapy Medications Available in Australia

Chemotherapy remains one of the primary treatment modalities for various cancer types in Australia. Common chemotherapy agents available include docetaxel, used for breast, lung, and prostate cancers; paclitaxel, which targets ovarian and breast cancers; and cisplatin, effective against testicular, ovarian, and lung cancers. Gemcitabine is widely prescribed for pancreatic and bladder cancers, whilst fluorouracil is a cornerstone treatment for colorectal and gastric cancers. Carboplatin provides an alternative to cisplatin with potentially fewer side effects for compatible cancer types.

These medications work by targeting rapidly dividing cells, though they can affect healthy cells as well, requiring careful monitoring and management. Australian pharmacies stock these medications under strict protocols, and patients receive them through accredited cancer centres and hospitals. The choice of chemotherapy depends on cancer staging, patient health status, and previous treatment history, with oncologists regularly assessing treatment efficacy and adjusting protocols as needed.

Targeted Therapies and Biological Agents

Targeted cancer therapies represent a significant advancement in oncology, offering more precise treatment approaches than traditional chemotherapy. In Australia, several targeted therapies are available, including trastuzumab for HER2-positive breast cancers, which specifically targets cancer cells with this genetic marker. Bevacizumab inhibits tumour blood vessel formation, slowing cancer growth in colorectal, lung, and breast cancers. Imatinib revolutionised treatment for chronic myeloid leukaemia and gastrointestinal stromal tumours by targeting specific genetic mutations.

Erlotinib and gefitinib address EGFR mutations in non-small cell lung cancer, whilst cetuximab targets colorectal and head-and-neck cancers. These biological agents often have improved side effect profiles compared to conventional chemotherapy, though they require specific genetic testing to determine patient suitability. Australian pathology services provide comprehensive genetic and molecular testing to identify patients who would benefit from these targeted approaches. The development of these therapies has significantly improved survival outcomes for eligible patients across various cancer types.

Hormonal Therapies and Endocrine Treatments

Hormonal therapy plays a vital role in treating hormone-sensitive cancers, particularly breast and prostate cancers. Tamoxifen remains a standard treatment for oestrogen-receptor-positive breast cancer, working by blocking oestrogen’s effects on cancer cells. Aromatase inhibitors, including letrozole, anastrozole, and exemestane, reduce oestrogen production in postmenopausal women, effectively preventing cancer recurrence and progression. Fulvestrant acts as a selective oestrogen receptor degrader, offering an alternative mechanism for advanced breast cancer management.

For prostate cancer, androgen deprivation therapies such as goserelin, leuprolide, and bicalutamide are commonly prescribed to slow tumour growth. These hormonal treatments are often used as long-term maintenance therapy, with treatment duration depending on individual risk factors and cancer stage. Australian oncologists carefully balance the benefits of hormonal therapy against potential side effects, including bone density changes and cardiovascular considerations. Regular monitoring through pathology tests and imaging ensures treatment effectiveness whilst maintaining quality of life for patients receiving these therapies.

Supportive Care and Side Effect Management

Managing side effects is an essential component of cancer treatment, helping patients maintain quality of life throughout their therapy. Comprehensive supportive care addresses the various challenges that arise during cancer treatment and recovery.

Key medications and treatments used in supportive cancer care include:

• Antiemetics such as ondansetron, granisetron, and metoclopramide to effectively manage chemotherapy-induced nausea and vomiting
• Growth factors like pegfilgrastim and filgrastim that support bone marrow recovery by stimulating white blood cell production, reducing infection risk during treatment
• Allopurinol and rasburicase to prevent hyperuricaemia and tumour lysis syndrome, particularly important in haematological cancers
• Pain management medications, ranging from paracetamol to stronger opioids, tailored to individual needs under strict medical supervision
• Sleep aids and anxiety medications to address psychological impacts of cancer treatment
• Nutritional supplements to support overall health and recovery
• Dermatological preparations to manage skin reactions from radiation and targeted therapies
• Antifungal agents to prevent opportunistic infections in immunocompromised patients

Australian cancer centres provide comprehensive supportive care programmes, with pharmacists and nurses educating patients about medication management and self-care strategies. This holistic approach to cancer treatment recognises that minimising side effects improves treatment compliance and overall wellbeing.

Cancer Prevention, Screening, and Long-Term Monitoring

Prevention and early detection significantly improve cancer outcomes, with several screening programmes available throughout Australia. Bowel cancer screening through faecal immunochemical tests can detect early-stage disease when treatment is most effective. Mammography programmes identify breast cancer in its earliest stages, particularly in women over 50. Cervical screening via cervical cytology and HPV testing has dramatically reduced cervical cancer incidence. Skin cancer prevention emphasises sun protection and regular professional skin checks, given Australia’s high UV exposure.

Medications like tamoxifen and raloxifene may be considered for high-risk individuals to reduce breast cancer development. After completing cancer treatment, long-term monitoring involves regular medical reviews, imaging studies, and blood tests to detect recurrence early. Lifestyle modifications including smoking cessation, alcohol moderation, healthy weight maintenance, and regular exercise reduce cancer recurrence risk. Australian cancer registries track outcomes and support survivorship programmes, helping patients transition from active treatment to long-term follow-up care and management of treatment effects. Your pharmacist can provide additional guidance on maintaining your health and wellbeing during and after cancer treatment.